Jonathan Keats, PhD 🇨🇦
@pedalheadphx.bsky.social
🇨🇦 boiling in the Arizona desert and not riding my bikes enough. Cancer researcher focused on multiple myeloma and clinical genomics at TGen, part of City of Hope. Creator of MyelomaSky and Sequencing Tech feeds. Director, Collaborative Sequencing Center
How old is this plane, don’t remember the last time I saw volume and channel controls in the arm rest
October 7, 2025 at 3:04 PM
How old is this plane, don’t remember the last time I saw volume and channel controls in the arm rest
Yesterday the FDA approved the third T-cell engager against BCMA, Lynozyfic (linvoseltamab) from Regeneron, following on the earlier EMA approval this spring. This is the 20th drug approved to treat #myeloma in just over 20 years. For those that are interested here is the updated approval timeline.
July 3, 2025 at 4:49 PM
Yesterday the FDA approved the third T-cell engager against BCMA, Lynozyfic (linvoseltamab) from Regeneron, following on the earlier EMA approval this spring. This is the 20th drug approved to treat #myeloma in just over 20 years. For those that are interested here is the updated approval timeline.
First world problem, finished fund raiser but cant drive home cause my car is updating, mental not don’t schedule software updates for 10pm
April 11, 2025 at 5:10 AM
First world problem, finished fund raiser but cant drive home cause my car is updating, mental not don’t schedule software updates for 10pm
Apparently the reason you see no workers is the project is now on hold thanks to future funding worries. How many construction jobs lost? How many future jobs lost? Now my office is quieter, not sure that is a long term positive
March 31, 2025 at 6:41 PM
Apparently the reason you see no workers is the project is now on hold thanks to future funding worries. How many construction jobs lost? How many future jobs lost? Now my office is quieter, not sure that is a long term positive
One more round of giving the same talk to the 8th grade students at my daughters school
February 20, 2025 at 9:01 PM
One more round of giving the same talk to the 8th grade students at my daughters school
Great meeting yesterday with the @cityofhope.bsky.social and @tgenresearch.bsky.social myeloma team working to bring rapid whole genome sequencing to myeloma patients. Special thanks to Suzie Nason helping make this dream a reality.
February 12, 2025 at 7:06 PM
Great meeting yesterday with the @cityofhope.bsky.social and @tgenresearch.bsky.social myeloma team working to bring rapid whole genome sequencing to myeloma patients. Special thanks to Suzie Nason helping make this dream a reality.
NICE!! any_of() does work when there are extras in the dictionary. I'd sorted out the filtering but this is much cleaner looking. THANKS SO MUCH for the great inspiration.
January 31, 2025 at 9:03 PM
NICE!! any_of() does work when there are extras in the dictionary. I'd sorted out the filtering but this is much cleaner looking. THANKS SO MUCH for the great inspiration.
#ASH24 myeloma, gene expression review of genes in 17p del patients only PKMYT1 is over expressed and KO is lethal, drug exist that seems to be uniquely effective. High potential for benefit observation from @nikhilmunshi.bsky.social lab
December 9, 2024 at 7:01 PM
#ASH24 myeloma, gene expression review of genes in 17p del patients only PKMYT1 is over expressed and KO is lethal, drug exist that seems to be uniquely effective. High potential for benefit observation from @nikhilmunshi.bsky.social lab
#ASH24 myeloma, IRF4 in myeloma, identified genes regulating ITF3, AiRID1a and IRF4 bind the same region, MED12 impairs both MYC and IRF4, great science
December 9, 2024 at 6:43 PM
#ASH24 myeloma, IRF4 in myeloma, identified genes regulating ITF3, AiRID1a and IRF4 bind the same region, MED12 impairs both MYC and IRF4, great science
David Jung from UofC showing inactivation of TRAF3 is associated pan resistance to TCE, interesting but also associated with target loss in patients
December 8, 2024 at 8:42 PM
David Jung from UofC showing inactivation of TRAF3 is associated pan resistance to TCE, interesting but also associated with target loss in patients
#ASH24 myeloma, Adolfo Alena from Mount Sinai, MDSC with S100A8/9 expression associated with poor Car-t outcome, incubation of CAr-t with S100A8/9 has linear effect on inhibiting cytotoxic effect, can be salvaged with a blocking antibody. Great talk
December 8, 2024 at 8:12 PM
#ASH24 myeloma, Adolfo Alena from Mount Sinai, MDSC with S100A8/9 expression associated with poor Car-t outcome, incubation of CAr-t with S100A8/9 has linear effect on inhibiting cytotoxic effect, can be salvaged with a blocking antibody. Great talk
#ASH24 myeloma, 16/27 patients were successfully tested with WGS on circulating tumor cells. Major question is how much drop out might exist. Still a tour de force by the @ireneghobrial.bsky.social lab
December 8, 2024 at 6:58 PM
#ASH24 myeloma, 16/27 patients were successfully tested with WGS on circulating tumor cells. Major question is how much drop out might exist. Still a tour de force by the @ireneghobrial.bsky.social lab
Dr Puig, presenting on myeloma response criteria in the mass spec era #ASH24 1050 paired BM/serum samples from 350 patients. Mass spec clearly better than IFE alone. Even predicts PFS in CR patients. Even suggest in CR, marrow evaluation only useful for MRD. Super valuable study
December 8, 2024 at 6:11 PM
Dr Puig, presenting on myeloma response criteria in the mass spec era #ASH24 1050 paired BM/serum samples from 350 patients. Mass spec clearly better than IFE alone. Even predicts PFS in CR patients. Even suggest in CR, marrow evaluation only useful for MRD. Super valuable study
Luca Bertamini presenting on CTC in myeloma PERSEUS trail with D-VRd - ASCT, pre treatment euroflow CTC, 80%, 0.175% cutoff, 15.3% of patients, high-risk genetics and high CTC showed no benefit to quad, less likely to acheive MRDneg
December 8, 2024 at 5:42 PM
Luca Bertamini presenting on CTC in myeloma PERSEUS trail with D-VRd - ASCT, pre treatment euroflow CTC, 80%, 0.175% cutoff, 15.3% of patients, high-risk genetics and high CTC showed no benefit to quad, less likely to acheive MRDneg
#ASH24 interesting Greek study with patients stopping lenalidomide maintenance after 3 years of MRD negativity. Showed 27.5 median time to shift to MRD positive. Two plus years of treatment and most patient respond to Len again when MRD+
December 8, 2024 at 12:15 AM
#ASH24 interesting Greek study with patients stopping lenalidomide maintenance after 3 years of MRD negativity. Showed 27.5 median time to shift to MRD positive. Two plus years of treatment and most patient respond to Len again when MRD+
Circling the desert waiting for a chance to land in San Diego. The pre #ASH24 rush is already started before I even land for what I just realized is my 25th ASH meeting. Loki g forward to seeing friends and colleagues, and building the MyelomaSky community on this platform
December 5, 2024 at 5:14 PM
Circling the desert waiting for a chance to land in San Diego. The pre #ASH24 rush is already started before I even land for what I just realized is my 25th ASH meeting. Loki g forward to seeing friends and colleagues, and building the MyelomaSky community on this platform
Anyone else see this issue on their NovaSeq X Plus? Side A in lane 8 has a noticeable increase in percent one mismatch reads in bclConvert stats
November 24, 2024 at 11:27 PM
Anyone else see this issue on their NovaSeq X Plus? Side A in lane 8 has a noticeable increase in percent one mismatch reads in bclConvert stats
Day2 of the annual fall retreat for the Juniper program, an NCI moonshot PE-CGS funded study. Lots of valuable interactions between everyone involved
November 19, 2024 at 7:22 PM
Day2 of the annual fall retreat for the Juniper program, an NCI moonshot PE-CGS funded study. Lots of valuable interactions between everyone involved
When in Albuquerque try something new, very good coffee
November 19, 2024 at 3:36 PM
When in Albuquerque try something new, very good coffee
@sci-bri.bsky.social nice to see old friends here and cute dog
November 14, 2024 at 5:11 PM
@sci-bri.bsky.social nice to see old friends here and cute dog
Starting up the first international meeting on high-risk myeloma
October 24, 2024 at 2:01 PM
Starting up the first international meeting on high-risk myeloma
It finally arrived, I can’t vote, GreenCard, but I pay more in taxes than most, and when you add my medical insurance it’s close to what I’d pay in Canada, so feel like I should at least voice my opinion on the election #GirlDad #independent
October 22, 2024 at 4:05 AM
It finally arrived, I can’t vote, GreenCard, but I pay more in taxes than most, and when you add my medical insurance it’s close to what I’d pay in Canada, so feel like I should at least voice my opinion on the election #GirlDad #independent